Literature DB >> 22614184

Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer.

Daniel B Kendler1, Fernanda Vaisman, Rossana Corbo, Rosângela Martins, Mario Vaisman.   

Abstract

PURPOSE: To evaluate the predictive capacity of clinical and laboratory variables in relation to the success of ablation. The variables studied were as follows: thyroglobulin (Tg) in hypothyroidism, before ablation; age; gender; type of carcinoma (papillary or follicular); the tumor stage; the administered activity of I; and the whole-body scan 7 days after ablation.
MATERIALS AND METHODS: Retrospective review of the medical records of all patients who were admitted to the therapeutic room to undergo treatment with I, from 1998 to 2007. Of the records reviewed, 96 patients fulfilled the inclusion criteria and had no exclusion criteria. A negative whole-body scan and Tg in hypothyroidism <2 ng/mL, after 6 to 12 months of treatment, were considered as successful ablation.
RESULTS: The dosage of Tg in hypothyroidism, measured before the ablation, was the only independent predictor of ablation success in multivariate analysis (P < 0.0001), and the optimal cutoff for this cohort was 18 ng/mL. On univariate analysis, the high-risk staging was predictor of ablation failure.
CONCLUSION: The measurement of Tg in hypothyroidism before ablation might be useful if added to the routine evaluation of patients before I treatment because it was a good predictor of successful ablation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614184     DOI: 10.1097/RLU.0b013e31824852f8

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  15 in total

1.  Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer.

Authors:  Heeyoung Kim; Seong-Jang Kim; In-Joo Kim; Keunyoung Kim; Sojung Kim; Bo Hyun Kim; Sang Soo Kim; Jeon Yoon Kyung
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

2.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

3.  Iodine Uptake Patterns on Post-ablation Whole Body Scans are Related to Elevated Serum Thyroglobulin Levels After Radioactive Iodine Therapy in Patients with Papillary Thyroid Carcinoma.

Authors:  Geum-Cheol Jeong; Minchul Song; Hee Jeong Park; Jung-Joon Min; Hee-Seung Bom; Sang-Geon Cho; Ki Seong Park; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Seong Young Kwon
Journal:  Nucl Med Mol Imaging       Date:  2016-05-13

4.  Thyroglobulin-Based Risk Factor Repositioning for Determining Radioactive Iodine Activity in Patients with Papillary Thyroid Carcinoma: a Multicenter Retrospective Cohort Study.

Authors:  Subin Jeon; Seong Young Kwon; Sang-Woo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2022-06-18

5.  Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.

Authors:  Fabian Pitoia; Erika Abelleira; Graciela Cross
Journal:  Endocrine       Date:  2016-09-21       Impact factor: 3.633

6.  Correlation of Consecutive Serum Thyroglobulin Levels During Hormone Withdrawal and Failure of Initial Radioiodine Ablation in Thyroid Cancer Patients.

Authors:  Hyukjin Yoon; Sung Hoon Kim; Joo Hyun O; Ye Young Seo; Yeongjoo Lee; Hyoungwoo Kim; Jiyoung Ryu
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

7.  Preablative Stimulated Thyroglobulin and Thyroglobulin Reduction Index as Decision-Making Markers for Second Radioactive Iodine Therapy in Patients with Structural Incomplete Response.

Authors:  Lihua Wang; Canhua Yun; Fengyan Huang; Juan Xiao; Yanli Ju; Fang Cheng; Wei Zhang; Hongying Jia
Journal:  Cancer Manag Res       Date:  2021-07-05       Impact factor: 3.989

8.  Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy.

Authors:  Kyung-Hee Kim; Min-Hee Kim; Ye-Jee Lim; Ihn Suk Lee; Ja-Seong Bae; Dong-Jun Lim; Ki Hyun Baek; Jong Min Lee; Moo-Il Kang; Bong-Yun Cha
Journal:  Int J Endocrinol       Date:  2015-01-12       Impact factor: 3.257

9.  Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer.

Authors:  Germán A Jimenez Londoño; Ana Maria Garcia Vicente; Julia Sastre Marcos; Francisco Jose Pena Pardo; Mariano Amo-Salas; Manuel Moreno Caballero; Maria Prado Talavera Rubio; Beatriz Gonzalez Garcia; Niletys Dafne Disotuar Ruiz; Angel Maria Soriano Castrejón
Journal:  Eur Thyroid J       Date:  2018-07-05

10.  The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg/TSH Ratio on the Therapeutic Effect of 131I Treatment in DTC Patients.

Authors:  Wei Zheng; Zhongying Rui; Xuan Wang; Ning Li; Jian Tan; Wei Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.